Management of cardiovascular risk factors with pioglitazone combination therapies in type 2 diabetes: an observational cohort study

10-Year Follow-up of Intensive Glucose Control in Type 2 Diabetes

Rury R. Holman, Sanjoy K. Paul, M. Angelyn Bethel et al. · New England Journal of Medicine · 2008 · 7.6K citations · Full text

Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial

John Dormandy, B Charbonnel, D.J.A. Eckland et al. · The Lancet · 2005 · 4.1K citations · Full text

Diabetes Management, Cardiovascular Disease, Health Policy +10

Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom prospective diabetes study (UKPDS: 23)

R. C. Turner, Helen Millns, H. A. W. Neil et al. · BMJ · 1998 · 2K citations · Full text

Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary: The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD)

European Heart Journal · 2006 · 1.6K citations · Full text

Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial

Philip Home, Stuart Pocock, Henning Beck‐Nielsen et al. · The Lancet · 2009 · 1.4K citations

Open-label Trial, Diabetes Management, Cardiovascular Disease +10